CareDx to acquire SBT Resolver™ HLA Typing Products from Illumina
January 24 2017 - 4:01PM
CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused
on the discovery, development and commercialization of clinically
differentiated, high-value diagnostic solutions for transplant
recipients, announces that it has signed an agreement with
Illumina, Inc. (Nasdaq:ILMN) for the acquisition of Conexio SBT
Resolver™ products and Assign™ SBT analysis software for high
resolution HLA typing.
SBT Resolver assay designs and Assign SBT software advances have
been key to the global implementation of HLA typing. This
technology set the benchmark for high-resolution HLA typing and the
recently enhanced SBT Resolver assays and Assign SBT v4.7 software
continue to provide innovative, high quality HLA typing.
CareDx, through its recently acquired Olerup franchise, has a
strong global presence in the pre-transplant HLA typing market.
Olerup has successfully distributed the Conexio SBT product line
since 2011.
“We see CareDx well-positioned to take ownership of Conexio’s
SBT business since the Olerup franchise previously distributed
these products. The sale of Conexio’s capillary electrophoresis SBT
portfolio permits Illumina to focus on next-generation sequencing
products for HLA typing,” said Rob Brainin, Vice President and
General Manager, Applied Genomics at Illumina, Inc.
“This acquisition allows us to continue to build our transplant
business as we commercialize our existing core products, launch new
products and now also can leverage inorganic growth options such as
Conexio’s SBT. Illumina has been a terrific partner and strategic
investor. We are excited about adding the SBT product line and the
capabilities of a great team in Fremantle, Australia to CareDx.”
said Peter Maag, CEO of CareDx.
About CareDxCareDx, Inc., based in Brisbane, California, is a
molecular diagnostics company focused on the discovery, development
and commercialization of clinically differentiated, high-value,
non-invasive diagnostic surveillance solutions for transplant
recipients. The Company has commercialized AlloMap®, a gene
expression test that aids clinicians in identifying heart
transplant recipients. CareDx is also pursuing the
development of additional products for post-transplant monitoring
of other solid organs that use a variety of technologies, including
next generation sequencing, to detect donor-derived cell-free DNA
to monitor the health of organs after transplantation.
CareDx, with its presence through Olerup, also develops,
manufactures, markets and sells high quality products that increase
the chance of successful transplants by facilitating a better match
between a donor and a recipient of stem cells and organs.
For more information, please visit: www.CareDx.com.
Forward Looking Statements This press release contains
forward-looking statements including, but not limited to our
proposed acquisition of Conexio SBT Resolver™ products and Assign
SBT™ analysis software for high resolution HLA typing, and our
business, research, development and commercialization efforts.
These forward-looking statements are based upon information that is
currently available to us and our current expectations, speak only
as of the date hereof, and are subject to numerous risks and
uncertainties, including risk associated with completing the
acquisition and the continued successful research, development and
planned commercialization of our technologies, that are described
in our filings with the SEC, including the Annual Report on Form
10-K for the fiscal year ended December 31, 2015 filed by us with
the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for
the fiscal quarter ended September 30, 2016 filed by us with the
SEC on November 14, 2016. Any of these may cause our actual
results, performance or achievements to differ materially and
adversely from those anticipated or implied by our forward-looking
statements. We expressly disclaim any obligation, except as
required by law, or undertaking to update or revise any such
forward-looking statements.
Investor Relations Contact
Jamar Ismail, Vice President
Westwicke Partners, LLC
T: +1 415-513-1282
E: jamar.ismail@westwicke.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024